Kowa Company Limited

Shunji Takemura

Yoshinori Kyotani

Takeshi Doi

Masahiro Tamura

Seiichi Sato

Tatsuhiko Kodama

Toshiaki Oda

Yukiyoshi Yamazaki

Takahiro Kitamura

Masahiro Nishikawa

Hiromichi Shigyo

Masao Ohkuchi

Tomoyuki Koshi

Hideo Yoshizaki

Kyoko Yasuoka

Junko Totsuka

Tetsuya Ishikawa

Hajime Yamada

Hiroyuki Ishiwata

Masanori Ashikawa

Yoshiharu Miyake

Takuya Hara

Takahiro Ito

Manabu Shibasaki

Junya Tagashira

Toshiharu Arai

Toshiharu Morimoto

Tatsuaki Nishiyama

Yuichiro Tabunoki

Takatoshi Ozawa

Ryota Shigemi

Akiyasu Kouketsu

The present invention provides a low molecular weight compound having EPO production-promoting action and/or hemoglobin production-promoting action. The present invention relates to a fused piperidine compound represented by the following general formula (1): (wherein, ring A represents a Caryl group or 5- to 10-membered heterocyclic group, X represents N&#x2014;R, a sulfur atom or an oxygen atom, R, R, R, Rand Rindependently represent a hydrogen atom, Calkyl group or Ccycloalkyl group, and R, Rand Rindependently represent a hydrogen atom or halogen atom), or a salt thereof, or a solvate thereof.

Fused piperidine compound and pharmaceutical containing same

To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj&#xf6;gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

Pyridine-3-carboxyamide derivative

The present invention relates a specific tetrahydroisoquinoline compound which is useful as a chemokine receptor type 3 (CCR3) antagonist, and a pharmaceutical composition comprising the same as an active ingredient. The tetrahydroisoquinoline compound of the present invention is useful for the treatment or prevention of a disease in which CCR3 participates.

Tetrahydroisoquinoline compound

A phenylpyridazine derivative represented by the formula (1): Wherein, R1, R2, R3, X, Y, Z and n have the same meaning as defined in the specification; or a salt thereof, or a medicine containing the compound. The present invention provides water-soluble phenylpyridazine derivatives and medicines containing them, which have excellent inhibitory activity against interleukin-&#x3b2; production, high water solubility and high oral absorbability.

Water-soluble phenylpyridazine derivative and medicine containing the same

Compounds having the formula (1): wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

Water-soluble phenylpyridazine compounds and compositions containing the same

Compounds having the formula (1):wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represent a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represent a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to medicinal compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

A cyclic amine compound represented by the following general formula (1):wherein, These compounds have inhibitory effects on both cell adhesion and cell infiltration and are useful as anti-asthmatic agents, anti-allergic agents, anti-rheumatic agents, anti-arteriosclerotic agents, anti-inflammatory agents, anti-Sjogren's syndrome agents or the like.

Cyclic amine compounds and pharmaceutical composition containing the same

Compounds having the formula (1):wherein Rrepresents an alkyl or alkenyl group, Rand Reach independently represents a hydrogen atom or an alkyl, hydroxyalkyl, dihydroxyalkyl or alkynyl group, or Rand Rmay be fused together with the adjacent nitrogen atom to form a substituted or unsubstituted, nitrogen-containing, saturated heterocyclic group, X, Y and Z each independently represents a hydrogen atom, an alkyl group, a halogen atom or the like, and n stands for an integer of from 1 to 5; and also to pharmaceutical compositions containing them. These compounds have inhibitory activity against IL-1&#x3b2; production, high water solubility and good oral absorbability.

Unsymmetrical cyclic diamine compound

Growing community of inventors

Hachioji, Japan

Shunji Takemura